Spine Regenerative Portfolio Target spine surgeons and orthopedics with PURcore, PURfiberXP and PURmarrow360 to address bone growth, bioactive matrices, and autologous cell therapies in spinal procedures; position PUR Biologics as an integrated regenerative solution for bone healing and cartilage regeneration.

US Market Expansion Capitalize on the US launch momentum by pursuing distribution partnerships and hospital group contracts; as a small company, channel partners can accelerate adoption, training, and implementation across regional spine centers.

Autologous Advantage Emphasize autologous bone marrow and cell therapies to reduce immunogenic risk and regulatory complexity, appealing to hospitals and surgery centers seeking safer, patient-derived regenerative options.

Competitive Differentiation Position PUR Biologics as a nimble innovator with proprietary bioactive matrices and moldable scaffolds that complement larger players' portfolios, offering flexible formats and targeted clinical education.

Bundled Solutions Offer bundled, multi-product regeneration programs combining PURcore, PURfiberXP and PURmarrow360 for spine and joint indications, plus training and service support to drive multi-product adoption in hospitals and ASCs.